Ahead of its Q1 report due on 12 May, Relais announced the acquisition of a Swedish company, Skeppbr...
Company activities Through Fastator’s focus on acquisitions and development of existing real estate...
Redeye leaves its view on Xspray following today’s Q1 report.
Redeye maintains its valuation of Optomed after the Q1 report.
Under det första kvartalet 2022 erhöll Maven Wireless AB (”Maven” eller ”Bolaget”) 35 orders från 14...
Bra organisk tillväxt och högsta förvärvstakten någonsin Den organiska tillväxten är volatil mellan ...
Starkt resultat i Q1'22 drivet av Sawn Wood och Joinery Bergs Timber rapporterade EBITDA på 82 mkr i...
Blygsamma intäkter Rapporten för Q1 2022 var odramatisk och som förväntat var intäkterna låga i vänt...
Redeye leaves a comment on the Q1 report Initiator Pharma released earlier this morning.
Infrea redovisade ett starkt kvartal trots säsongsmässiga variationer.
Solid growth, especially in Circular Energy Some necessary growing pains lead to higher opex 10x ‘23...
Sales up 26% y-o-y, -3% vs. ABGSCe We lift ‘22e adj.
Redeye saw positive sales development and Opex in line with estimates.
Coor inleder året starkt och växer omsättningen med goda 27 procent samtidigt som lönsamheten stärkt...
Etteplan saw strong growth and good profitability in Q1.
The Q1 results and notes on Pohjola Hospital support the view Pihlajalinna is advancing in terms of ...
Q1 sales were 7% below our estimate (no consensus available), driven by higher return rates as well ...
EBIT +7% vs. ABGSCe; guides for increased UAC in Q2 We raise ‘23e-‘24e EBIT on higher growth for Sh...
Q1 EBIT of SEK 216m, 40% above ABGSC AUM growth of 2% q-o-q in Q1, in line with ABGSC The stock shou...
Redeye states that the Q1 report was strong and in line with estimates.
